Lymphomas

Expert faculty review and share their insights on key findings in lymphomas presented at the 2023 ASH Annual Meeting.

Share

Program Content

Activities

  • Lymphoma Updates 2023
    Conference to Clinic: Lymphoma Updates 2023
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 11, 2024

  • ASH 2023: Lymphomas and CLL
    Key Studies in Lymphomas and CLL: Independent Coverage of ASH 2023
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 06, 2024

    Expires: March 05, 2025

Activities

VALENTINE-PTCL01
VALENTINE-PTCL01: Primary Results of Phase II Trial of Valemetostat Tosylate in Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

ELARA 3-Year Follow-up
Phase II ELARA: 3-Year Follow-up of Tisagenlecleucel in R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

TRANSCEND CLL 004 Update
TRANSCEND CLL 004: 24-Mo Follow-up of Lisocabtagene Maraleucel in Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

EPCORE NHL 5
EPCORE NHL-5: Results From Arm 1 of a Phase Ib/II Trial Evaluating SC Epcoritamab + Lenalidomide in Relapsed/Refractory DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

1L Mosunetuzumab SC for FL
Mosunetuzumab SC as First-line Therapy for Patients With High Tumor Burden Follicular Lymphoma: Results of a Phase II Study
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

ELM-2 Exploratory ctDNA Analysis
ELM-2 Exploratory Analysis: Association Between ctDNA-Assessed Measurable Residual Disease Status and PFS With Odronextamab in R/R FL and DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

AN + AD in Early cHL
Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine in Early-Stage Classical Hodgkin Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

ELEVATE TN: 6 Yr Update
ELEVATE-TN 6-Yr Update: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

TRANSCEND FL at ASH 2023
TRANSCEND FL: Lisocabtagene Maraleucel as Second-Line Therapy for Patients With High-Risk R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

SWOG S1826
SWOG S1826: Nivolumab-AVD vs BV-AVD in Older Patients (Aged ≥60 Years) With Advanced Stage Classic Hodgkin Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

BOVen in 1L TP53mut MCL
BOVen: Phase II Trial of Zanubrutinib, Obinutuzmab, and Venetoclax in Treatment-Naive TP53-Mutated Mantle Cell Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

ELM-2 Final Analysis
ELM-2: Final Analysis From Phase II Trial of Odronextamab in Relapsed/Refractory DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

SYMPATICO
SYMPATICO: Phase III Trial of Ibrutinib + Venetoclax vs Ibrutinib + Placebo for Patients With R/R Mantle Cell Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Faculty

cover img faculity

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.